帕博利珠单抗-GVD方案治疗复发/难治经典型霍奇金淋巴瘤:多中心II期试验5年更新
该II期试验评估帕博利珠单抗联合吉西他滨、长春瑞滨和脂质体多柔比星(帕博利珠单抗-GVD)在适合移植的复发/难治经典型霍奇金淋巴瘤患者中的疗效。中位随访57个月,估计5年无进展生存率和总生存率分别为91%和94%,未发现新的安全性信号。
要点
- 帕博利珠单抗-GVD在适合移植的复发/难治经典型霍奇金淋巴瘤中5年PFS达91%。
- 38例可评估患者中CR率95%,35例(92%)仅2周期即达CR。
- 36例(95%)患者接受了大剂量化疗联合自体干细胞挽救。
核心结论
- 帕博利珠单抗-GVD在适合移植的复发/难治经典型霍奇金淋巴瘤中显示持久疗效,5年PFS和OS分别为91%和94%。
研究设计与样本
- 多中心II期试验(NCT03618550),纳入39例适合移植的复发/难治经典型霍奇金淋巴瘤患者。
- 方案为帕博利珠单抗200mg IV(第1天)、吉西他滨1000mg/m2 IV(第1、8天)、长春瑞滨20mg/m2 IV(第1、8天)、脂质体多柔比星15mg/m2 IV(第1、8天),21天为一周期,后续行大剂量化疗联合自体干细胞挽救。
主要发现
- 38例可评估患者中,最多4周期帕博利珠单抗-GVD后CR率和ORR分别为95%和100%。
- 35例(92%)仅2周期即达CR,36例(95%)接受了大剂量化疗联合自体干细胞挽救。
- 中位随访57个月,1例按方案治疗后复发,2例死于非复发或治疗相关原因,估计5年PFS和OS分别为91%和94%。
- 延长随访未发现新的安全性信号。
临床怎么用
- 对于适合移植的复发/难治经典型霍奇金淋巴瘤,帕博利珠单抗-GVD可作为高效诱导方案,多数患者2周期即达CR并顺利桥接自体干细胞移植。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
A phase II trial assessed the safety and efficacy of pembrolizumab, gemcitabine, vinorelbine, and liposomal doxorubicin (pembrolizumab-GVD) in transplant-eligible patients with relapsed/refractory (rel/rel) cHL, and demonstrated a complete response (CR) rate of 95% and progression-free survival (PFS) of 100% at 13.5 months (NCT03618550). We present an updated analysis of this trial at 5 years. Eligible patients received pembrolizumab 200mg intravenous (IV) (day 1), gemcitabine 1,000mg/m2 IV (days 1 and 8), vinorelbine 20mg/m2 IV (days 1 and 8), and liposomal doxorubicin 15mg/m2 IV (days 1 and 8) in 21-day cycles, followed by high-dose chemotherapy and autologous stem cell rescue (HDT/ASCR). Of 39 enrolled patients, 41% had primary refractory disease and 38% relapsed within 1 year of first-line treatment. In 38 response-evaluable patients, the CR and overall response rates after up to 4 cycles of pembrolizumab-GVD were 95% and 100%, respectively, with 35 patients (92%) attaining CR after only 2 cycles of therapy. Thirty-six (95%) patients underwent HDT/ASCR. After a median follow-up of 57 months, 1 patient experienced disease recurrence after per-protocol therapy, and 2 patients died from non-relapse or treatment-related causes. Estimated 5-year PFS and OS were 91% and 94%, respectively. No new safety signals were identified with extended follow-up.
引用
- Patel K, Shah GL, Schöder H, et al. Pembrolizumab-GVD in relapsed or refractory Hodgkin lymphoma: 5-year update of a multicenter phase 2 trial. Blood. 2026. PMID: 42825495. doi:10.1182/blood.2026035115
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。